Navigation Links
Malaria drug target raises hopes for new treatments
Date:12/22/2013

Scientists have taken an important step towards new malaria treatments by identifying a way to stop malaria parasites from multiplying.

In a study published in Nature Chemistry, they show that blocking the activity of an enzyme called NMT in the most common malaria parasite prevents mice from showing symptoms and extends their lifespan. The team are working to design molecules that target NMT more potently, and hope to start clinical trials of potential treatments within four years.

A recent study estimated that 1.2 million people died from malaria in 2010. Although a variety of antimalarial drugs are available, some strains of the parasite are resistant to treatment. These strains are becoming more common, with treatment failures reported across multiple frontline drugs. If acute illness is cured, the parasite can remain dormant in the blood and return to cause illness later. Malaria vaccines have been researched intensively, but none have been introduced into clinical practice.

The new study shows that NMT is involved in a wide range of essential processes in the parasite cell, including the production of proteins that enable malaria to be transmitted between humans and mosquitoes, and proteins that enable malaria to cause long-term infection.

The researchers have tested a handful of molecules that block the activity of NMT in the parasite living inside human red blood cells, and in mice, but further refinement will be needed before a treatment is ready to be tested in humans.

Dr Ed Tate, from the Department of Chemistry at Imperial College London, who led the project, said: "The drug situation for malaria is becoming very serious. Resistance is emerging fast and it's going to be a huge problem in the future.

"Finding an enzyme that can be targeted effectively in malaria can be a big challenge. Here, we've shown not only why NMT is essential for a wide range of important processes in the parasite, but also that we can de
'/>"/>

Contact: Gail Wilson
gail.wilson@imperial.ac.uk
44-207-594-6702
Imperial College London
Source:Eurekalert

Page: 1 2

Related biology news :

1. Malaria conference looks to Israels past for modern solutions
2. Study finds new vulnerability in malaria parasite
3. Using data to fight malaria
4. Control malaria by segmenting sleeping arrangements
5. New research finds potential risk for millions in Africa believed resistant to vivax malaria
6. Vivax malaria may be evolving around natural defense
7. Low-dose treatment may block malaria transmission
8. New malaria vaccines roadmap targets next generation products by 2030
9. Holograms offer hope in fight against malaria, study suggests
10. CWRU grants Disease Diagnostic Group option on malaria diagnostic device
11. NIH fellowship helps researcher fight malaria, understand mosquito immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... researchers in nanotechnology, chemistry and biology now have access to ... the world. The new Spectral Imaging Facility, opened this fall, ... laser scanning confocal microscope, the first commercial machine of its ... Research of Santa Barbara and the confocal microscope system by ...
... in 1702, it was Anton van Leeuwenhoek who first described ... contraction of a stalk tethering the cell body of a ... Little did van Leeuwenhoek imagine that more than 300 years ... for speed and power in the nano world of cellular ...
... study in Botswana, Harvard School of Public Health researchers ... resource-poor settings, who receive antiretroviral (ARV) therapy, can achieve ... fully supported health care delivery system and infrastructure help ... 2005 issue of the Journal of Acquired Immune Deficiency ...
Cached Biology News:Similar Stem Cells In Insect And Human Gut 2HIV-infected adults in Botswana respond positively to ARV therapy public treatment program 2
(Date:8/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast ... 2015 on Monday, August 10, 2015 at 4:30 p.m. ... and chief executive officer, will lead the call. On ... for the second quarter 2015. The call ... Halozyme,s corporate website and a recording will be made ...
(Date:8/3/2015)... Mass. , Aug. 3, 2015  Merck KGaA, ... for innovative and top-quality high-tech products in the healthcare, ... with the US-based company Nano-C, their development and launch ... of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... in the growing OPV sector. Novel derivatives: ...
(Date:8/3/2015)... , August 3, 2015 According ... on 3D Cell Culture: Asia ... Market Research, the global 3D cell culture market was valued at ... expand at a CAGR of 29.1% to account for ... Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... are generally complicated and therefore often rather difficult to ... report on new methods which not only produce outstanding ... starting materials but also do not need expensive instrumentation. ... This is exactly what Jamil Elias and ...
... Mylan Inc. (Nasdaq: MYL ) today announced that ... principal amount of senior notes through a reopening of its Senior ... are being offered as additional notes under an existing indenture under ... Senior Notes due 2020 on May 19, 2010 . The ...
... Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies from ... , (Logo:   http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the 2010 ...
Cached Biology Technology:Empa grows 'sea urchin'-shaped structures 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
...
Biology Products: